Novo Nordisk A/S understated the impact of lookalike weight-loss injections on its market share before lowering its 2025 ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Novo Nordisk is scheduled to report results for the second quarter on Wednesday. Here is what you need to know: PROFIT FORECAST: The company pre-released preliminary second-quarter numbers last week, ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

When it was riding high, Novo Nordisk could have done M&A to reduce its dependence on obesity treatments. It didn’t.

Shares of Novo Nordisk ( NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...

Novo Nordisk, the Danish maker of the wildly popular Ozempic and Wegovy drugs used for weight loss, was downgraded due to ...

Novo Nordisk A/V (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Novo Nordisk rode Ozempic's success to becoming Europe's top company. Now it's faltering and its CEO is out. Provided by Dow Jones May 16, 2025, 1:38:00 PM ...